These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12691863)

  • 21. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
    Berruti A; Piovesan A; Torta M; Raucci CA; Gorzegno G; Paccotti P; Dogliotti L; Angeli A
    Br J Cancer; 1996 Jun; 73(12):1581-7. PubMed ID: 8664134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
    Alcaraz A; González-López R; Morote J; de la Piedra C; Meseguer C; Esteban E; Climent M; González-Gragera B; Alvarez-Ossorio JL; Chirivella I; Mellado B; Lara PC; Vázquez F; Contreras JA; Carles J; Murias A; Calderero V; Comet-Batlle J; González-Del Alba A; León-Mateos L; Mañas A; Segarra J; Lassa A; González-Enguita C; Méndez MJ; Samper P; Unda M; Mahillo-Fernández I; Bellmunt J;
    Br J Cancer; 2013 Jul; 109(1):121-30. PubMed ID: 23799855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
    J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases.
    Zafeirakis A; Papatheodorou G; Arhontakis A; Gouliamos A; Vlahos L; Limouris GS
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):103-13. PubMed ID: 19662405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases].
    Xin Y; Han B; Lou J; Wu J; Niu Y
    Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):947-53. PubMed ID: 20959067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer.
    Lumachi F; Santeufemia DA; Del Conte A; Mazza F; Tozzoli R; Chiara GB; Basso SM
    Anticancer Res; 2013 Jun; 33(6):2593-6. PubMed ID: 23749913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M; Yonese J; Fukui I; Ogata E
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
    Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
    Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reference intervals for bone turnover markers in Spanish premenopausal women.
    Guañabens N; Filella X; Monegal A; Gómez-Vaquero C; Bonet M; Buquet D; Casado E; Cerdá D; Erra A; Martinez S; Montalá N; Pitarch C; Kanterewicz E; Sala M; Surís X; Torres F;
    Clin Chem Lab Med; 2016 Feb; 54(2):293-303. PubMed ID: 26088062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
    Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD
    Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A variation in Bone Alkaline Phosphatase levels that correlates positively with bone loss and normal levels of aminoterminal propeptide of collagen I in girls with anorexia nervosa.
    Calero JA; Muñoz MT; Argente J; Traba ML; Méndez-Dávila C; García-Moreno C; de la Piedra C
    Clin Chim Acta; 1999 Jul; 285(1-2):121-9. PubMed ID: 10481928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reference intervals for serum concentrations of three bone turnover markers for men and women.
    Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A
    Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R; Thölix E
    Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
    Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
    J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
    Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.